Friday 6 November 2026 Export XNCR’s income statement to Excel — free account

Xencor, Inc.

XNCR Healthcare Biotechnology

Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.

Revenue: +17.5%
EPS: +29.3%
Free cash flow: −52.9%

Quarter to June 2026, against a year earlier

36.11 2.06 +6.05%

Follow XNCR

Alert me

Market cap: $2.5B
P/E: 0.0×
Fwd P/E: −9.9×
Dividend yield: —
F-score: 3/9
Altman Z: 1.73
Beneish M: −2.86
Dividend safety: n/a

Overview

Xencor, Inc. (XNCR) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Xencor, Inc. (XNCR) trades at a P/S ratio of 24.8×. Over the past ten years it has ranged from 3.5× (August 2025) to 110× (July 2015); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/XNCR/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Xencor, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/XNCR/metrics/ps-ratio">Xencor, Inc. (XNCR) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	9.1×	(33.09%)
FY2024	13.5×	73.43%
FY2023	7.8×	(17.07%)
FY2022	9.4×	10.48%
FY2021	8.5×	(58.15%)
FY2020	20.3×	63.99%
FY2019	12.4×	(47.05%)
FY2018	23.4×	62.62%
FY2017	14.4×	51.46%
FY2016	9.5×	(53.70%)

Period	P/S ratio	Change
Jun 2026	11.6×	24.82%
Mar 2026	9.3×	2.98%
Dec 2025	9.1×	55.68%
Sep 2025	5.8×	46.32%
39 more quarters	Free account

Against its own ten years

Low 3.5× High 110×

Ten-year median 12.6×

Current reading's percentile 90

Company	P/S ratio
PHVS Pharvaris N.V. compare	n/m
MBX MBX Biosciences, Inc. compare	n/m
ADMA ADMA Biologics Inc compare	5.7×
ZLAB Zai Lab Limited Unsponsored ADR compare	5.7×
BEAM Beam Therapeutics Inc. compare	18.6×
RCUS Arcus Biosciences, Inc. compare	22.8×
XNCR Xencor, Inc.	24.8×
RXRX Recursion Pharmaceuticals, Inc. compare	27.9×
NAMS NewAmsterdam Pharma Company N.V. compare	91.1×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Xencor, Inc. (XNCR) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on XNCR

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on XNCR

Stockrow Weekly